You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar) » Olmesartan (Benicar) and kidney disease
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:protocol:olmesartan:kidney_disease [10.25.2018] – [Benefits of angiotensin receptor blockers] sallieqhome:protocol:olmesartan:kidney_disease [08.13.2019] – [Elevated kidney values tend to be temporary] sallieq
Line 7: Line 7:
  
  
-===== Subclinical kidney infection ===== 
  
-Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:pathogenesis:th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:pathogenesis::microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test. 
- 
-Once patients activate the [[home:pathogenesis:innate_immunity|innate immune system]] with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests. 
  
  
Line 45: Line 41:
  
  //**Biff Palmer,** Nephrology at the University of Texas Southwestern// (({{pubmed>long:13679467}})) </blockquote>  //**Biff Palmer,** Nephrology at the University of Texas Southwestern// (({{pubmed>long:13679467}})) </blockquote>
 +
 +"Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function"  (({{pubmed>long:24062331}}))
 +
 +===== Subclinical kidney infection =====
 +
 +Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:pathogenesis:th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:pathogenesis::microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test.
 +
 +Once patients activate the [[home:pathogenesis:innate_immunity|innate immune system]] with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests.
 ===== Benefits of olmesartan for patients with kidney disease ===== ===== Benefits of olmesartan for patients with kidney disease =====
  
Line 55: Line 59:
 MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage.
  
-The benefits of olmesartan on patients with kidney inflammation include:+The benefits of olmesartan on patients with kidney inflammation include
  
   * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed>long:17130263}}))   * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed>long:17130263}}))
Line 87: Line 91:
  
 ==== Animal studies ==== ==== Animal studies ====
 +
 +[[http://hdl.handle.net/1807/96258|.Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.]]
  
 Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed>long:16985512}})) Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed>long:16985512}}))
Line 95: Line 101:
 {{tag>kidneys  Science}} {{tag>kidneys  Science}}
 ===== Notes and comments ===== ===== Notes and comments =====
 +
 +Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate  <del>PMID</del> https://www.sciencedirect.com/science/article/pii/S0085253815549466
  
  
home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.